Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i> -Mutant Gliomas

2014192 citationsJournal Articlebronze Open Access

Authors

Hiroaki Wakimoto · Translational Research in Oncology

Shota Tanaka · Center for Neuro-Oncology

William T. Curry · Massachusetts Institute of Technology

Franziska Loebel · Massachusetts General Hospital

Dan Zhao · Harvard University

Kensuke Tateishi · Massachusetts Institute of Technology

Juxiang Chen

Abstract

A subset of IDH-mutant gliomas with mutations in driver oncogenes has a more malignant phenotype in patients. Identification of these alterations may provide an opportunity for use of targeted therapies in these patients. Clin Cancer Res; 20(11); 2898-909. ©2014 AACR.

Topics & Keywords

Glioma Diagnosis and Treatment Cancer, Hypoxia, and Metabolism Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 20, Issue 11, pp. 2898-2909

DOI: 10.1158/1078-0432.ccr-13-3052

Field-Weighted Citation Impact: 6.96